NOVA MSC Bhd, a leading provider of industry-focused application software and services for the healthcare sector, has embarked in a slew of strategic initiatives to enhance its operational and financial capabilities through external investments.
This comes about following the inking of share subscription agreements (SSA) with Jostar Investment VCC and Mark Investment Group VCC for its subsidiaries Dex-Lab Pte Ltd and EyRIS Pte Ltd.
Dex-Lab which is known for developing DEXIE, a humanoid social robot for dementia care, and EyRIS, renowned for its AI-driven SELENA+ system for early detection of eye diseases, will benefit from the fresh capital to further their innovative projects.
The SSA for Dex-Lab entails Jostar and Mark Investment subscribing to new shares for a total consideration of S$10 mil (RM34.5 mil), thus ensuring Dex-Lab remains a 45% directly-owned subsidiary of Nova MSC with the ACE Market-listed company retaining control over the board of directors.
Similarly, the SSA for EyRIS will see Jostar and Mark Investment subscribing to new shares for a total consideration of US$10 mil (RM46.5 mil) which transforms EyRIS into an associate company of Nova MSC.
“We are thrilled to partner with investors who share our enthusiasm for technological innovation,” commented Nova MSC’s chairman Sunny Loh of the two deals.
“Their support underscores the transformative potential of our projects. The integration of social robots like DEXIE into eldercare demonstrates how technology can significantly enhance emotional support and companionship for the elderly while improving their overall well-being.
As for the AI-driven SELENA+ system for early detection of eye diseases, Loh said it exemplifies the critical role of deep learning in healthcare by enabling timely diagnosis and intervention.
“These advancements represent technological milestones and highlight our commitment to making a positive impact on the world through digital transformation and innovative solutions,” he enthused.
“The additional funding will support our subsidiaries’ growth and innovation, particularly in advancing AI (artificial intelligence) and robotics technologies. We remain committed to driving sustainable growth and creating long-term value for our shareholders.”
Dex-Lab’s development of DEXIE, a social robot designed for the eldercare industry, combines cutting-edge hardware and software to provide therapeutic and activity programs for seniors, particularly those with dementia.
Meanwhile, its EyRIS’ SELENA+, a deep learning system for early detection of eye diseases such as diabetic retinopathy, glaucoma and age-related macular degeneration, continues to make strides. EyRIS’ collaboration with Australia’s Optometrist Warehouse on a ground-breaking study further emphasises the global potential of AI in healthcare.
At the close of today’s mid-day trading, Nova MSC was up 0.5 sen or 2.38% to 21.5 sen with 9.11 million shares traded, thus valuing the company at RM285 mil. – Aug 1, 2025
